Anika Therapeutics (ANIK) 10-K 27 Feb 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Feb. 10, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	Anika Therapeutics, Inc.
Entity Central Index Key	898,437
Trading Symbol	anik
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		14,211,672
Entity Public Float			$ 460,209,312
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Shell Company	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 89,042	$ 133,256
Investments	69,972	24,000
Accounts receivable, net of reserves of $1,525 and $1,914 at December 31, 2018 and December 31, 2017, respectively	20,775	23,825
Inventories, net	21,300	22,035
Prepaid expenses and other current assets	1,854	3,211
Total current assets	202,943	206,327
Property and equipment, net	54,111	56,183
Other long-term assets	4,897	1,254
Intangible assets, net	9,191	10,635
Goodwill	7,851	8,218
Total assets	278,993	282,617
Current liabilities:
Accounts payable	3,143	6,747
Accrued expenses and other current liabilities	8,146	6,326
Total current liabilities	11,289	13,073
Other long-term liabilities	550	660
Deferred tax liability	3,542	5,393
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively	0	0
Common stock, $.01 par value; 90,000 and 60,000 shares authorized, 14,210 and 14,688 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively	142	147
Additional paid-in-capital	50,763	68,617
Accumulated other comprehensive loss	(5,526)	(4,784)
Retained earnings	218,233	199,511
Total stockholders’ equity	263,612	263,491
Total liabilities and stockholders’ equity	$ 278,993	$ 282,617

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts receivable, reserves	$ 1,525	$ 1,914
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,250	1,250
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	90,000	60,000
Common stock, shares issued (in shares)	14,210	14,688
Common stock, shares outstanding (in shares)	14,210	14,688

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 105,555	$ 113,420	$ 103,379
Operating expenses:
Cost of product revenue	31,280	27,364	24,027
Research & development	18,190	18,787	10,732
Selling, general & administrative	34,336	21,540	18,013
Total operating expenses	83,806	67,691	52,772
Income from operations	21,749	45,729	50,607
Interest and other income, net	1,458	473	263
Income before income taxes	23,207	46,202	50,870
Provision for income taxes	4,485	14,386	18,323
Net income	$ 18,722	$ 31,816	$ 32,547
Basic net income per share:
Basic net income per share (in dollars per share)	$ 1.30	$ 2.18	$ 2.22
Basic weighted average common shares outstanding (in shares)	14,442	14,575	14,682
Diluted net income per share:
Net income (in dollars per share)	$ 1.27	$ 2.11	$ 2.15
Diluted weighted average common shares outstanding (in shares)	14,689	15,068	15,116
Net income	$ 18,722	$ 31,816	$ 32,547
Foreign currency translation adjustment	(742)	2,533	(668)
Comprehensive income	17,980	34,349	31,879
Product [Member]
Revenue	105,531	107,783	102,932
Service [Member]
Revenue	$ 24	$ 5,637	$ 447

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2015	15,037
Balance at Dec. 31, 2015	$ 150	$ 81,685	$ 135,662	$ (6,649)	$ 210,848
Issuance of common stock for equity awards (in shares)	121
Issuance of common stock for equity awards	$ 1	1,006			1,007
Tax benefit related to equity awards		647			647
Stock-based compensation expense		3,392			3,392
Repurchase of common stock (in shares)	(531)
Repurchase of common stock	$ (5)	(24,995)			(25,000)
Net income			32,547		32,547
Other comprehensive Income (loss)				(668)	(668)
Balance (in shares) at Dec. 31, 2016	14,627
Balance at Dec. 31, 2016	$ 146	61,735	168,209	(7,317)	222,773
Issuance of common stock for equity awards (in shares)	61
Issuance of common stock for equity awards	$ 1	313			314
Stock-based compensation expense		5,807			5,807
Net income			31,816		31,816
Other comprehensive Income (loss)				2,533	2,533
Balance (in shares) at Dec. 31, 2017	14,688
Balance at Dec. 31, 2017	$ 147	68,617	199,511	(4,784)	263,491
Cumulative effect of change in accounting for stock-based compensation		762	(514)		248
Issuance of common stock for equity awards (in shares)	362
Issuance of common stock for equity awards	$ 4	2,882			2,886
Stock-based compensation expense		11,046			11,046
Repurchase of common stock (in shares)	(806)
Repurchase of common stock	$ (8)	(29,992)			(30,000)
Net income			18,722		18,722
Other comprehensive Income (loss)				(742)	(742)
Retirement of common stock for minimum tax withholdings (in shares)	(34)
Retirement of common stock for minimum tax withholdings	$ (1)	(1,790)			(1,791)
Balance (in shares) at Dec. 31, 2018	14,210
Balance at Dec. 31, 2018	$ 142	$ 50,763	$ 218,233	$ (5,526)	$ 263,612

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net income	$ 18,722	$ 31,816	$ 32,547
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	5,910	4,290	3,734
Loss on disposal of fixed assets	152	150
Stock-based compensation expense	11,046	5,807	3,392
Deferred income taxes	(1,817)	(1,198)	(65)
Provision for doubtful accounts	57	1,609	52
Provision for inventory	4,419	695	654
Accretion to amortized cost of investments	(371)
Changes in operating assets and liabilities:
Accounts receivable	2,914	2,674	(6,201)
Inventories	(7,577)	(6,521)	(1,738)
Prepaid expenses, other current and long-term assets	899	(1,454)	(898)
Accounts payable	(1,671)	3,890	(5,059)
Accrued expenses, other current and long-term liabilities	1,313	(1,313)	1,582
Income taxes payable	922	367	(3,552)
Net cash provided by operating activities	34,918	40,812	24,448
Cash flows from investing activities:
Proceeds from maturity of investments	46,000	41,500	46,500
Purchase of investments	(91,601)	(45,000)	(39,249)
Purchase of property and equipment	(4,656)	(8,980)	(14,014)
Net cash (used in) investing activities	(50,257)	(12,480)	(6,763)
Cash flows from financing activities:
Repurchase of common stock	(30,000)		(25,000)
Tax payments related to witholdings on vested restricted stock	(1,790)
Proceeds from exercise of equity awards	2,886	314	1,007
Net cash (used in) provided by financing activities	(28,904)	314	(23,993)
Exchange rate impact on cash	29	349	(138)
Increase (Decrease) in cash and cash equivalents	(44,214)	28,995	(6,446)
Cash and cash equivalents at beginning of period	133,256	104,261	110,707
Cash and cash equivalents at end of period	89,042	133,256	104,261
Supplemental disclosure of cash flow information:
Cash paid for income taxes	5,560	15,088	22,826
Non-cash Investing Activities:
Purchases of property and equipment included in accounts payable and accrued expenses	351	1,891	1,257
Build-to-suit lease agreement			$ 1,723

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	1. Anika Therapeutics, Inc. (the “Company”) is a global, integrated orthopedic and regenerative medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not At the Company’s annual stockholders’ meeting on May 31, 2018, 60 90 90 June 6, 2018. not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Anika Therapeutics, Inc. and its wholly owned subsidiaries, Anika Securities, Inc. (a Massachusetts Securities Corporation), and Anika Therapeutics S.r.l. (“Anika S.r.l.”). All intercompany balances and transactions have been eliminated in consolidation. Foreign Currency Translation The functional currency of the Company’s foreign subsidiary is the Euro. Assets and liabilities of the foreign subsidiary are translated using the exchange rate existing on each respective balance sheet date. Revenues and expenses are translated using the average exchange rates for the period. The translation adjustments resulting from this process are included in stockholders’ equity as a component of accumulated other comprehensive income (loss) which resulted in a gain (loss) from foreign currency translation of ( $0.7 $2.5 $0.7 December 31, 2018, 2017, 2016, Gains and losses resulting from foreign currency transactions are recognized in the consolidated statements of operations. Recorded balances that are denominated in a currency other than the functional currency are remeasured to the functional currency using the exchange rate at the balance sheet date and gains or losses are recorded in the statements of operations. The Company recognized a gain (loss) from foreign currency transactions of ( $0.4 $0.7 $0.3 December 31, 2018, 2017, 2016, Fair Value Measurements Fair value is defined as the price that would be received from selling an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs that may • Level 1 1 • Level 2 not • Level 3 not The Company’s financial assets have been classified as Levels 1. third Allowance for Doubtful Accounts The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance for doubtful accounts, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer credit-worthiness, current economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms. A summary of activity in the allowance for doubtful accounts is as follows: December 31, 2018 2017 2016 Balance, beginning of the year $ 1,914 $ 194 $ 167 Amounts provided 57 1,609 52 Amounts recovered (360 ) - - Amounts written off - (6 ) (16 ) Translation adjustments (86 ) 117 (9 ) Balance, end of the year $ 1,525 $ 1,914 $ 194 Revenue Recognition - General The Company adopted the guidance the FASB’s Accounting Standards Codification (“ASC”) Revenue from Contracts with Customers 606 January 1, 2018. 606 not not no 605, Revenue Recognition Pursuant to ASC 606, five The Company has agreements with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc. (“Mitek”) that include the grant of certain licenses, performance of development services, and the supply of product at Mitek’s option. Revenues from the agreements with Mitek represent 73% December 31, 2018. 2016. no The Company has agreements with other customers that may not The Company’s typical supply agreements represent a promise to deliver product at the customer’s discretion that are considered options. The Company assessed if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The majority of the Company’s supply agreements do not Certain of the Company’s agreements include sales-based royalties and milestones. As the Company considered the license to be the predominant item to which the royalties relate for these agreements, sales-based royalties and milestones are only recognized when the later of the underlying sale occurs or the performance obligation to which some or all of the sales-based royalty has been satisfied (or partially satisfied). This is generally in the same period that the Company’s licensees complete their product sales in their territory, for which the Company is contractually entitled to a percentage-based royalty. Revenue from sales-based royalties is included in product revenues. Product Revenue The Company sells its products principally to a number of distributors (i.e., its customers) under legally-enforceable, executed contracts. The Company’s distributors subsequently resell the products to sub-distributors and health care providers, among others. The Company recognizes revenue from product sales when the distributor obtains control of the Company’s product, which typically occurs upon shipment to the distributor, in return for agreed-upon, fixed-price consideration. Performance obligations are generally settled quickly after purchase order acceptance; therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. The Company’s payment terms are consistent with prevailing practice in the respective markets in which the Company does business. Most of the Company’s distributors make payments based on fixed-price contract terms, which are not one not not Some of the Company’s distributor agreements have volume based discounts with tiered pricing which are generally prospective in nature. These prospective discounts together with any free-of-charge sample units offered are evaluated as potential material rights. If the prospective discounts or free-of-charge sample units are considered material rights, these would be separate performance obligations and a portion of the sales transaction price is allocated to the material right. Revenue allocated to the material right is recognized when the additional goods are transferred to the customer or when the option expires. During 2018, not The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due, and may January 1, 2018 December 31, 2018 $0. Generally, distributor contracts contain Free on Board (FOB) or Ex-Works (EXW) shipping point terms where the customer pays the shipping company directly for all shipping and handling costs. In those contracts in which the Company pays for the shipping and handling, the associated costs are generally recorded along with the product sale at the time of shipment in cost of product revenue when control over the products has transferred to the customer. The Company does not not not not one 340 40 25 4. Included as a component of product revenue is sales-based royalty revenue, which represents the utilization of the Company’s intellectual property licensed by its commercial partners. The Company records royalty revenues based on estimated net sales of licensed products as reported to us by the Company’s commercial partners. Differences between actual and estimated royalty revenues have not Licensing, Milestone and Contract Revenue The agreements with Mitek include variable consideration such as contingent development and regulatory milestones. As of the date of adoption of ASC 606, one no not Cash and Cash Equivalents The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within three 90 Investments The Company’s investments consist of U.S. treasury bills. The Company has designated all investments as available-for-sale, and therefore such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net. Interest is recorded when earned. Investments with original maturities greater than approximately three one one three All of the Company’s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the extent and length of time the investment's fair value has been lower than its cost basis, the financial condition and near-term prospects of the investee, extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the security, and whether or not December 31, 2018 2017, not not not not Concentration of Credit Risk and Significant Customers The Company has no two The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. As of December 31, 2018 2017, 75% 68%, no 10% Inventories Inventories are stated at the lower of standard cost and net realizable value, with approximate cost determined using the first first not The Company’s policy is to write-down inventory when conditions exist that suggest inventory may not When recorded, inventory write-downs are intended to reduce the carrying value of inventory to its net realizable value. Inventory $25.1 $3.8 and $22.0 December 31, 2018 2017, $3.5 $1.7 may Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives, which are typically: Asset Estimated useful life Computer equipment and software 3-10 Furniture and fixtures 5-7 Equipment 5-20 Leasehold improvements Shorter of useful life or term of lease Maintenance and repairs are charged to expense when incurred; additions and improvements are capitalized. Fully depreciated assets are retained in the accounts until they are no no Construction-in-process is stated at cost, which includes the cost of construction and other direct costs attributable to the construction. Construction-in-process is not Goodwill and Acquired Intangible Assets Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable assets on the date of acquisition. Acquired In-Process Research and Development (“IPR&D”) represents the fair value assigned to research and development assets that the Company acquires that have not Goodwill and IPR&D are evaluated for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the acquired assets or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company’s stock price for a sustained period, or a reduction of its market capitalization relative to net book value. To conduct impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company’s annual assessment for impairment of goodwill as of November 30, 2018 To conduct impairment tests of IPR&D, the fair value of the IPR&D project is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&D project exceeds its fair value. The Company estimates the fair value for IPR&D using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including but not November 30, 2018 2017 Long-Lived Assets Long-lived assets primarily include property and equipment and intangible assets with finite lives. The Company’s intangible assets are comprised of purchased developed technologies, patents, and trade names. These intangible assets are carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line basis over the intangible assets' useful lives, which range from approximately five sixteen may not no Research and Development Research and development costs consist primarily of clinical trials, salaries and related expenses for personnel, and fees paid to outside consultants and outside service providers, including costs associated with licensing, milestone and contract revenue. Research and development costs are expensed as incurred. Stock-Based Compensation The Company has stock-based compensation plans under which it grants various types of equity-based awards, including restricted stock units (“RSUs”), restricted stock awards (“RSAs”), performance options, and stock options. The Company measures the compensation cost of award recipients’ services received in exchange for an award of equity instruments based on the grant date fair value of the underlying award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award. For performance-based options with financial and business milestone achievement targets, the Company recognizes expense using the graded vesting methodology over the service period. Compensation cost associated with performance-based options is based on the probable outcome of the performance conditions. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related stock-based compensation expense that will be recorded in the period of the change. If the performance targets are not no $0.7 $0.8 $0.3 2018, 2017, 2016, See Note 13, Equity Incentive Plan 10 Income Taxes The Company’s income tax expense includes U.S. and international income taxes. Certain items of income and expense are not not not Comprehensive Income Comprehensive income consists of net income and other comprehensive income (loss), which includes foreign currency translation adjustments. For the purposes of comprehensive income disclosures, the Company does not Segment Information Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its President and Chief Executive Officer. Based on the criteria established by ASC 280, Segment Reportin one Contingencies In the normal course of business, the Company is involved from time-to-time in various legal proceedings and other matters such as contractual disputes, which are complex in nature and have outcomes that are difficult to predict. The Company records accruals for loss contingencies to the extent that it concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company considers all relevant factors when making assessments regarding these contingencies. Although the outcomes of any potential legal proceedings are inherently difficult to predict, the Company does not Subsequent Events Events occurring subsequent to December 31, 2018 no Recent Accounting Pronouncements In February 2016, No. 2016 02, 842 2016 02 December 15, 2018. January 1, 2019 no may 2016 02 $20.0 $23.0 12 not 842. not In August 2018, No. 2018 15, 350 40 No. 2015 05, 2018 15 350 40 2018 15 December 15, 2019. 2018 15

Note 3 - Revenue by Product Gro

Note 3 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	3. Product revenue by product group is as follows: Years Ended December 31, 2018 2017 2016 Revenue Percentage Revenue Percentage Revenue Percentage Orthobiologics $ 93,556 89 % $ 93,816 87 % $ 89,695 87 % Dermal 396 0 % 2,755 3 % 2,759 3 % Surgical 5,514 5 % 5,262 5 % 5,427 5 % Other 6,065 6 % 5,950 5 % 5,051 5 % $ 105,531 100 % $ 107,783 100 % $ 102,932 100 % Product revenue from the Company’s sole significant customer, Mitek, as a percentage of the Company’s total product revenue was 73%, 73%, 75% December 31, 2018, 2017, 2016, ORTHOVISC became available for sale in the United States on March 1, 2004, ten December 2003. five 2012 2017, December 20, 2023. In December 2011, fifteen December 31, 2018, 2017, 2016, $0.0 $5.0 $0.0 $5.0 2017 2017 $100 12 Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue are as follows: Years Ended December 31, 2018 2017 2016 Total Percentage of Total Percentage of Total Percentage of Geographic Location: United States $ 85,351 81 % $ 92,905 82 % $ 83,972 81 % Europe 11,730 11 % 12,435 11 % 10,953 11 % Other 8,474 8 % 8,080 7 % 8,454 8 % Total $ 105,555 100 % $ 113,420 100 % $ 103,379 100 % On May 2, 2018, not no three March 31, 2018 $1.1 $0.9 March 31, 2018 Net long-lived assets, consisting of net property and equipment, are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they are relatively illiquid. Net tangible long-lived assets by principal geographic areas are as follows: Years Ended December 31, 2018 2017 United States $ 51,385 $ 52,828 Italy 2,726 3,355 Total $ 54,111 $ 56,183

Note 4 - Investments

Note 4 - Investments	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Cash and Cash Equivalents Disclosure [Text Block]	4. All of the Company’s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income (loss), net of related income taxes. The Company held U.S. treasury bills of $70.0 December 31, 2018. $24.0 December 31, 2017. December 31, 2018 December 31, 2017,

Note 5 - Fair Value Measurement

Note 5 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	5. The Company’s investments are all classified within Level 1 1 2 third not The classification of the Company’s cash equivalents and investments within the fair value hierarchy is as follows: Fair Value Measurements at Reporting Date Using December 31, 2018 Quoted Prices in Significant Other Significant Amortized Cost Cash equivalents: Money Market Funds $ 4,984 $ 4,984 $ - $ - $ 4,984 Investments: U.S. treasury bills $ 69,972 $ 69,972 $ - $ - $ 69,972 Fair Value Measurements at Reporting Date Using December 31, 2017 Quoted Prices in Significant Other Significant Amortized Cost Cash equivalents: Money market funds $ 5,893 $ 5,893 $ - $ - $ 5,893 Bank certificates of deposit 500 - 500 - 500 Total cash equivalents $ 6,393 $ 5,893 $ 500 $ - $ 6,393 Investments: Bank certificates of deposit $ 24,000 $ - $ 24,000 $ - $ 24,000 The Company did not 3 December 31, 2018 2017.

Note 6 - Earnings Per Share ("E

Note 6 - Earnings Per Share ("EPS")	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	6. Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the period. Unvested RSAs, although legally issued and outstanding, are not The following table provides share information used in the calculation of the Company's basic and diluted earnings per share: Years Ended December 31, 2018 2017 2016 Shares used in the calculation of basic earnings per share 14,442 14,575 14,682 Effect of dilutive securities: Stock options, SARs, RSAs and RSUs 247 493 434 Diluted shares used in the calculation of earnings per share 14,689 15,068 15,116 Stock options to purchase 0.7 0.5 0.4 December 31, 2018, 2017, 2016, 2018, 2017 2016 At December 31, 2018, 2017, 2016 42 0.1 0.1 On May 24, 2018, $30.0 $30.0 0.4 May 24, 2018 $41.41 60% On July 16, 2018, $12.0 July 16, 2018. 0.4 July 19, 2018. 0.8 $37.18 not On February 26, 2016, $25.0 $25.0 0.4 February 29, 2016 $46.40 On August 26, 2016, $7.5 August 26, 2016. 0.1 August 31, 2016. 0.5 $47.08

Note 7 - Inventories

Note 7 - Inventories	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	7. Inventories consist of the following: December 31, 2018 2017 Raw materials $ 13,688 $ 11,296 Work-in-process 4,626 6,062 Finished goods 6,819 4,677 Total $ 25,133 $ 22,035 Inventories $ 21,300 $ 22,035 Other long-term assets 3,833 - Other long-term assets include inventory expected to remain on hand beyond one December 31, 2018. As a result of the voluntary recall of certain production lots of the Company’s HYAFF-based products, more fully described in Note 3, $0.8 $1.3 $1.2 December 31, 2018.

Note 8 - Property and Equipment

Note 8 - Property and Equipment	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	8. Property and equipment is stated at cost and consists of the following: December 31, 2018 2017 Equipment and software $ 39,646 $ 37,137 Furniture and fixtures 2,014 1,947 Leasehold improvements 33,801 31,459 Construction in progress 2,720 5,830 Subtotal 78,181 76,373 Less accumulated depreciation (24,070 ) (20,190 ) Total $ 54,111 $ 56,183 Construction-in-progress at December 31, 2018 2017 2019. December 31, 2017 January 2018. Depreciation expense was $4.9 $3.3 $2.7 December 31, 2018, 2017, 2016,

Note 9 - Acquired Intangible As

Note 9 - Acquired Intangible Assets, Net	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	9. Intangible assets consist of the following: December 31, 2018 December 31, 2017 Gross Value Accumulated Accumulated Net Book Accumulated Accumulated Net Book Useful Developed technology $ 17,100 $ (2,824 ) $ (8,672 ) $ 5,604 $ (2,550 ) $ (7,723 ) $ 6,827 15 In-process research & development 4,406 (1,168 ) - 3,238 (1,015 ) 3,391 Indefinite Distributor relationships 4,700 (415 ) (4,285 ) - (415 ) (4,285 ) - 5 Patents 1,000 (169 ) (482 ) 349 (152 ) (431 ) 417 16 Elevess trade name 1,000 - (1,000 ) - - (1,000 ) - 9 Total $ 28,206 $ (4,576 ) $ (14,439 ) $ 9,191 $ (4,132 ) $ (13,439 ) $ 10,635 The Company performed an annual assessment of IPR&D intangible assets as of November 30, 2018. 2018 no Total amortization expense was $1.0 $1.0 $1.1 December 31, 2018, 2017, 2016, $1.0 2019, $1.0 2022, $2.1

Note 10 - Goodwill

Note 10 - Goodwill	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Goodwill Disclosure [Text Block]	10. The Company completed its annual impairment review as of November 30, 2018 no December 31, 2018, not may not December 31, Balance, beginning $ 8,218 Effect of foreign currency adjustments (367 ) Balance, ending $ 7,851

Note 11 - Accrued Expenses

Note 11 - Accrued Expenses	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	11. Accrued expenses consist of the following: December 31, 2018 2017 Compensation and related expenses $ 4,446 $ 2,893 Professional fees 1,989 448 Voluntary recall 116 - Research grants 400 419 Clinical trial costs 577 2,318 Income taxes payable 385 - Other 233 248 Total $ 8,146 $ 6,326 Included in Compensation and related expenses as of December 31, 2018 March 9, 2018. March 8, 2018 $0.3 one may February 28, 2019. $1.7 18 March 9, 2018, 13, Accrued liabilities related to the previously-described product recall of certain production lots of the Company’s HYAFF-based products, more fully described in Note 3, December 31, 2018 $0.1

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	12. Leasing Arrangements On October 9, 2015, 33,000 fifteen March 1, 2017. three six six no ninth $0.3 Construction of the new facility commenced during the first 2016. March 1, 2017, $3.1 $0.8 Rental expense in connection with the various facility leases totaled $1.8 $1.8 $1.3 December 31, 2018, 2017, 2016, 2017 first November 1, 2017 October 31, 2022, The Company’s future lease commitments as of December 31, 2018 2019 $ 1,879 2020 1,917 2021 1,924 2022 1,672 2023 414 2024 and thereafter 897 Total $ 8,703 Warranty and Guarantor Arrangements In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may not third no December 31, 2018 2017, no Legal Proceedings The Company is involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of potential legal proceedings are inherently difficult to predict, the Company does not

Note 13 - Equity Incentive Plan

Note 13 - Equity Incentive Plan	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	13. Equity Incentive Plan The Anika Therapeutics, Inc. 2017 “2017 June 13, 2017 may 2017 2.0 no 1.2 may 2017 0.9 December 31, 2018. The 2017 “2003 2003 2003 June 4, 2003 May 29, 2009 June 7, 2011 June 18, 2013 2011 June 7, 2011, 1.9 2013 June 18, 2013, 1.5 The Company may one four ten The Company estimates the fair value of stock options and SARs using the Black-Scholes valuation model. Fair value of restricted stock is measured by the grant-date price of the Company’s shares. Key input assumptions used to estimate the fair value of stock options and SARs include the exercise price of the award, the expected award term, the expected volatility of the Company’s stock over the option’s expected term, the risk-free interest rate over the award’s expected term, and the Company’s expected annual dividend yield. The expected volatility assumption is evaluated against the historical volatility of the Company’s common stock over a 4.5 The weighted-average grant-date fair value per share of stock options granted in 2018, 2017 2016 $20.01, $16.87 and $16.65, 2018, 2017, 2016 2018 2017 2016 Risk free interest rate 2.15% - 2.82% 1.60% - 1.86% 0.94% - 1.55% Expected volatility 37.12% - 45.61% 38.74% - 44.31% 47.33% - 51.61% Expected life (years) 4.0 - 4.5 4.0 4.5 Expected dividend yield 0.00% 0.00% 0.00% Stock Options and Restricted Stock The following table sets forth share information for stock-based compensation awards granted and exercised during the period ended December 31, 2018 2017: Twelve Months Ended December 31, 2018 2017 Grants: Stock options 199,970 440,688 RSAs 64,578 26,306 RSUs 15,457 9,970 Exercises: Stock options 284,548 12,941 SARs - 5,000 The Company recorded $11.0 $5.8 $3.4 December 31, 2018, 2017, 2016, $1.5 $0.4 $0.6 March 9, 2018, one $6.2 three March 31, 2018. The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows: 2018 2017 2016 Cost of product revenue $ (160 ) $ 439 $ 148 Research & development 851 564 467 Selling, general & administrative 10,355 4,804 2,777 Total stock-based compensation expense $ 11,046 $ 5,807 $ 3,392 The decrease in stock-based compensation expense within the cost of product revenue line item for the year ended December 31, 2018 The combined stock options and SARs activity for the year ended December 31, 2018 2018 Number of Weighted Options and SARs outstanding at beginning of year 1,327,200 $ 33.70 Granted 199,970 $ 58.11 Cancelled (104,629 ) $ 50.19 Expired (1,079 ) $ 46.49 Exercised (284,548 ) $ 10.14 Options and SARs outstanding at end of year 1,136,914 $ 42.06 All the 1,136,914 December 31, 2018 $42.06 $3.7 5.0 December 31, 2018. As of December 31, 2018, $4.4 2.4 The exercisable options and SARs at December 31, 2018 Number Weighted Avg Weighted Average Incentive stock options 139,674 $ 24.53 4.1 Non-qualified stock options 453,790 $ 40.74 3.2 Performance awards 100,963 $ 40.72 3.1 Stock appreciation rights 35,250 $ 6.36 1.1 The total intrinsic value of stock options and SARs exercised was $8.5 $0.5 $2.1 December 31, 2018, 2017 2016, The total fair value of stock options and SARs vested during the years ended December 31, 2018, 2017 2016 $6.7 $2.1 $1.3 The RSA and RSU activity for the year ended December 31, 2018 2018 Number of Weighted Unvested at Beginning of year 229,226 $ 42.47 Granted 80,035 $ 58.84 Cancelled (126,946 ) $ 42.47 Vested/Released (123,232 ) $ 50.80 Unvested at end of year 59,083 $ 47.26 The total fair value of RSAs and RSUs vested during the years ended December 31, 2018, 2017 2016 $6.8 $2.3 $1.0 December 31, 2018, 2017 2016 $58.84, $52.03 $38.11,

Note 14 - Employee Benefit Plan

Note 14 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	14. The Company’s U.S. employees are eligible to participate in the Company’s 401 may 140% 5% may $0.8 $0.6 $0.6 December 31, 2018, 2017, 2016,

Note 15 - Shareholder Rights Pl

Note 15 - Shareholder Rights Plan	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	15. On April 4, 2008, “2008 2008 April 8, 2018, not 2008

Note 16 - Income Taxes

Note 16 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	16. On December 22, 2017, “2017 35% 21% 2018. In accordance with Staff Accounting Bulletin No. 118, 2017 no 2017 not 2017 Income Tax Expense The components of the Company’s income before income taxes and its provision for (benefit from) income taxes consist of the following: Years ended December 31, 2018 2017 2016 Income before income taxes Domestic $ 26,227 $ 48,446 $ 50,181 Foreign (3,020 ) (2,244 ) 689 $ 23,207 $ 46,202 $ 50,870 Years ended December 31, 2018 2017 2016 Provision for (benefit from) income taxes: Current provision: Federal $ 4,783 $ 12,608 $ 14,982 State 1,644 2,737 3,265 Foreign 405 31 302 6,832 15,376 18,549 Deferred provision: Federal (992 ) (426 ) (70 ) State (152 ) (68 ) (84 ) Foreign (1,203 ) (496 ) (72 ) (2,347 ) (990 ) (226 ) Total provision $ 4,485 $ 14,386 $ 18,323 Deferred Tax Assets and Liabilities Significant components of the Company’s deferred tax assets and liabilities consist of the following: December 31, 2018 2017 Deferred tax assets: Net operating loss carry forward, foreign $ 1,382 $ 959 Stock-based compensation expense 3,148 2,309 Foreign currency exchange 363 265 Accrued expenses and other 818 496 Inventory reserve 1,500 740 Deferred tax assets $ 7,211 $ 4,769 December 31, 2018 2017 Deferred tax liabilities: Acquisition-related Intangibles $ (2,405 ) $ (2,743 ) Depreciation (8,348 ) (7,419 ) Deferred tax liabilities $ (10,753 ) $ (10,162 ) Net deferred tax liabilities $ (3,542 ) $ (5,393 ) Tax Rate The reconciliation between the U.S. federal statutory rate and the Company’s effective rate is summarized as follows: Years ended December 31, 2018 2017 2016 Statutory federal income tax rate 21.0 % 35.0 % 35.0 % State tax expense, net of federal benefit 5.5 % 4.8 % 4.5 % Impact of rate change on deferred taxes 0.0 % (4.9 %) 0.0 % Permanent items, including nondeductible expenses (1.4 %) 0.1 % 0.1 % State investment tax credit (0.2 %) (0.7 %) (0.1 %) Federal, state and foreign research and development credits (3.4 %) (1.4 %) (0.9 %) Foreign rate differential (0.4 %) 0.5 % (0.1 %) Domestic production deduction 0.0 % (2.8 %) (2.9 %) Stock compensation (4.8 %) (0.2 %) 0.1 % Non-deductible Section 162(m) compensation limitation 4.3 % 0.7 % 0.3 % Foreign derived intangible income deduction (1.3 %) 0.0 % 0.0 % Effective income tax rate 19.3 % 31.1 % 36.0 % As of December 31, 2018, $5.8 not Accounting for Uncertainty in Income Taxes The Company had no December 31, 2018 2017, The Company does not twelve December 31, 2018. In the normal course of business, Anika and its subsidiaries may 2015 2017 2012 2017 Upon the settlement of certain stock-based awards (i.e., exercise, vesting, forfeiture, or cancellation), the actual tax deduction is compared with cumulative financial reporting compensation cost, and any excess tax deduction related to these awards is considered a windfall tax benefit. With the adoption of ASU 2016 09 2017, $1.5 2018 $0.4 2017.

Note 17 - Revolving Credit Agre

Note 17 - Revolving Credit Agreement	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	17. On October 24, 2017, five $50.0 may $50.0 $100.0 0.50%, one 1.0%, 0.25% 1.75% 0.25% five December 31, 2018 2017, no The Credit Agreement contains customary representations, warranties, affirmative and negative covenants, including financial covenants, events of default and indemnification provisions in favor of the Lenders (as defined in the Credit Agreement). The covenants include restrictions governing the Company’s leverage ratio and interest coverage ratio, its incurrence of liens and indebtedness, and its entry into certain merger and acquisition transactions or dispositions and other matters, all subject to certain exceptions. The financial covenants require the Company not first

Note 18 - Quarterly Financial D

Note 18 - Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Quarterly Financial Information [Text Block]	18. Year 2018 Quarter ended Quarter ended Quarter ended Quarter ended Product revenue $ 26,950 $ 26,781 $ 30,542 $ 21,258 Total revenue 26,956 26,787 30,548 21,264 Cost of product revenue 7,001 8,282 8,152 7,845 Gross profit on product revenue 19,949 18,499 22,390 13,413 Net income $ 7,717 $ 7,599 $ 10,092 $ (6,686 ) Per common share information: Basic net income per share $ 0.54 $ 0.53 $ 0.69 $ (0.46 ) Basic common shares outstanding 14,168 14,237 14,652 14,679 Diluted net income per share $ 0.54 $ 0.53 $ 0.68 $ (0.46 ) Diluted common shares outstanding 14,299 14,377 14,915 14,679 Year 2017 Quarter ended Quarter ended Quarter ended Quarter ended Product revenue $ 28,884 $ 27,178 $ 28,340 $ 23,381 Total revenue 29,388 27,184 33,462 23,386 Cost of product revenue 8,716 6,250 6,315 6,083 Gross profit on product revenue 20,168 20,928 22,025 17,298 Net income $ 8,067 $ 6,887 $ 11,369 $ 5,493 Per common share information: Basic net income per share $ 0.55 $ 0.47 $ 0.78 $ 0.38 Basic common shares outstanding 14,596 14,579 14,588 14,576 Diluted net income per share $ 0.53 $ 0.46 $ 0.76 $ 0.37 Diluted common shares outstanding 15,141 15,115 15,044 15,043

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Anika Therapeutics, Inc. and its wholly owned subsidiaries, Anika Securities, Inc. (a Massachusetts Securities Corporation), and Anika Therapeutics S.r.l. (“Anika S.r.l.”). All intercompany balances and transactions have been eliminated in consolidation.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency of the Company’s foreign subsidiary is the Euro. Assets and liabilities of the foreign subsidiary are translated using the exchange rate existing on each respective balance sheet date. Revenues and expenses are translated using the average exchange rates for the period. The translation adjustments resulting from this process are included in stockholders’ equity as a component of accumulated other comprehensive income (loss) which resulted in a gain (loss) from foreign currency translation of ( $0.7 $2.5 $0.7 December 31, 2018, 2017, 2016, Gains and losses resulting from foreign currency transactions are recognized in the consolidated statements of operations. Recorded balances that are denominated in a currency other than the functional currency are remeasured to the functional currency using the exchange rate at the balance sheet date and gains or losses are recorded in the statements of operations. The Company recognized a gain (loss) from foreign currency transactions of ( $0.4 $0.7 $0.3 December 31, 2018, 2017, 2016,
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Fair value is defined as the price that would be received from selling an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs that may • Level 1 1 • Level 2 not • Level 3 not The Company’s financial assets have been classified as Levels 1. third
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance for doubtful accounts, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer credit-worthiness, current economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms. A summary of activity in the allowance for doubtful accounts is as follows: December 31, 2018 2017 2016 Balance, beginning of the year $ 1,914 $ 194 $ 167 Amounts provided 57 1,609 52 Amounts recovered (360 ) - - Amounts written off - (6 ) (16 ) Translation adjustments (86 ) 117 (9 ) Balance, end of the year $ 1,525 $ 1,914 $ 194
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition - General The Company adopted the guidance the FASB’s Accounting Standards Codification (“ASC”) Revenue from Contracts with Customers 606 January 1, 2018. 606 not not no 605, Revenue Recognition Pursuant to ASC 606, five The Company has agreements with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc. (“Mitek”) that include the grant of certain licenses, performance of development services, and the supply of product at Mitek’s option. Revenues from the agreements with Mitek represent 73% December 31, 2018. 2016. no The Company has agreements with other customers that may not The Company’s typical supply agreements represent a promise to deliver product at the customer’s discretion that are considered options. The Company assessed if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The majority of the Company’s supply agreements do not Certain of the Company’s agreements include sales-based royalties and milestones. As the Company considered the license to be the predominant item to which the royalties relate for these agreements, sales-based royalties and milestones are only recognized when the later of the underlying sale occurs or the performance obligation to which some or all of the sales-based royalty has been satisfied (or partially satisfied). This is generally in the same period that the Company’s licensees complete their product sales in their territory, for which the Company is contractually entitled to a percentage-based royalty. Revenue from sales-based royalties is included in product revenues. Product Revenue The Company sells its products principally to a number of distributors (i.e., its customers) under legally-enforceable, executed contracts. The Company’s distributors subsequently resell the products to sub-distributors and health care providers, among others. The Company recognizes revenue from product sales when the distributor obtains control of the Company’s product, which typically occurs upon shipment to the distributor, in return for agreed-upon, fixed-price consideration. Performance obligations are generally settled quickly after purchase order acceptance; therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. The Company’s payment terms are consistent with prevailing practice in the respective markets in which the Company does business. Most of the Company’s distributors make payments based on fixed-price contract terms, which are not one not not Some of the Company’s distributor agreements have volume based discounts with tiered pricing which are generally prospective in nature. These prospective discounts together with any free-of-charge sample units offered are evaluated as potential material rights. If the prospective discounts or free-of-charge sample units are considered material rights, these would be separate performance obligations and a portion of the sales transaction price is allocated to the material right. Revenue allocated to the material right is recognized when the additional goods are transferred to the customer or when the option expires. During 2018, not The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due, and may January 1, 2018 December 31, 2018 $0. Generally, distributor contracts contain Free on Board (FOB) or Ex-Works (EXW) shipping point terms where the customer pays the shipping company directly for all shipping and handling costs. In those contracts in which the Company pays for the shipping and handling, the associated costs are generally recorded along with the product sale at the time of shipment in cost of product revenue when control over the products has transferred to the customer. The Company does not not not not one 340 40 25 4. Included as a component of product revenue is sales-based royalty revenue, which represents the utilization of the Company’s intellectual property licensed by its commercial partners. The Company records royalty revenues based on estimated net sales of licensed products as reported to us by the Company’s commercial partners. Differences between actual and estimated royalty revenues have not Licensing, Milestone and Contract Revenue The agreements with Mitek include variable consideration such as contingent development and regulatory milestones. As of the date of adoption of ASC 606, one no not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within three 90
Marketable Securities, Policy [Policy Text Block]	Investments The Company’s investments consist of U.S. treasury bills. The Company has designated all investments as available-for-sale, and therefore such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net. Interest is recorded when earned. Investments with original maturities greater than approximately three one one three All of the Company’s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the extent and length of time the investment's fair value has been lower than its cost basis, the financial condition and near-term prospects of the investee, extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the security, and whether or not December 31, 2018 2017, not not not not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Significant Customers The Company has no two The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. As of December 31, 2018 2017, 75% 68%, no 10%
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of standard cost and net realizable value, with approximate cost determined using the first first not The Company’s policy is to write-down inventory when conditions exist that suggest inventory may not When recorded, inventory write-downs are intended to reduce the carrying value of inventory to its net realizable value. Inventory $25.1 $3.8 and $22.0 December 31, 2018 2017, $3.5 $1.7 may
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives, which are typically: Asset Estimated useful life Computer equipment and software 3-10 Furniture and fixtures 5-7 Equipment 5-20 Leasehold improvements Shorter of useful life or term of lease Maintenance and repairs are charged to expense when incurred; additions and improvements are capitalized. Fully depreciated assets are retained in the accounts until they are no no Construction-in-process is stated at cost, which includes the cost of construction and other direct costs attributable to the construction. Construction-in-process is not
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill and Acquired Intangible Assets Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable assets on the date of acquisition. Acquired In-Process Research and Development (“IPR&D”) represents the fair value assigned to research and development assets that the Company acquires that have not Goodwill and IPR&D are evaluated for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the acquired assets or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company’s stock price for a sustained period, or a reduction of its market capitalization relative to net book value. To conduct impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company’s annual assessment for impairment of goodwill as of November 30, 2018 To conduct impairment tests of IPR&D, the fair value of the IPR&D project is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&D project exceeds its fair value. The Company estimates the fair value for IPR&D using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including but not November 30, 2018 2017
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Long-Lived Assets Long-lived assets primarily include property and equipment and intangible assets with finite lives. The Company’s intangible assets are comprised of purchased developed technologies, patents, and trade names. These intangible assets are carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line basis over the intangible assets' useful lives, which range from approximately five sixteen may not no
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs consist primarily of clinical trials, salaries and related expenses for personnel, and fees paid to outside consultants and outside service providers, including costs associated with licensing, milestone and contract revenue. Research and development costs are expensed as incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company has stock-based compensation plans under which it grants various types of equity-based awards, including restricted stock units (“RSUs”), restricted stock awards (“RSAs”), performance options, and stock options. The Company measures the compensation cost of award recipients’ services received in exchange for an award of equity instruments based on the grant date fair value of the underlying award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award. For performance-based options with financial and business milestone achievement targets, the Company recognizes expense using the graded vesting methodology over the service period. Compensation cost associated with performance-based options is based on the probable outcome of the performance conditions. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related stock-based compensation expense that will be recorded in the period of the change. If the performance targets are not no $0.7 $0.8 $0.3 2018, 2017, 2016, See Note 13, Equity Incentive Plan 10
Income Tax, Policy [Policy Text Block]	Income Taxes The Company’s income tax expense includes U.S. and international income taxes. Certain items of income and expense are not not not
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income Comprehensive income consists of net income and other comprehensive income (loss), which includes foreign currency translation adjustments. For the purposes of comprehensive income disclosures, the Company does not
Segment Reporting, Policy [Policy Text Block]	Segment Information Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its President and Chief Executive Officer. Based on the criteria established by ASC 280, Segment Reportin one
Commitments and Contingencies, Policy [Policy Text Block]	Contingencies In the normal course of business, the Company is involved from time-to-time in various legal proceedings and other matters such as contractual disputes, which are complex in nature and have outcomes that are difficult to predict. The Company records accruals for loss contingencies to the extent that it concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company considers all relevant factors when making assessments regarding these contingencies. Although the outcomes of any potential legal proceedings are inherently difficult to predict, the Company does not
Subsequent Events, Policy [Policy Text Block]	Subsequent Events Events occurring subsequent to December 31, 2018 no
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, No. 2016 02, 842 2016 02 December 15, 2018. January 1, 2019 no may 2016 02 $20.0 $23.0 12 not 842. not In August 2018, No. 2018 15, 350 40 No. 2015 05, 2018 15 350 40 2018 15 December 15, 2019. 2018 15

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Allowance for Credit Losses on Financing Receivables [Table Text Block]	December 31, 2018 2017 2016 Balance, beginning of the year $ 1,914 $ 194 $ 167 Amounts provided 57 1,609 52 Amounts recovered (360 ) - - Amounts written off - (6 ) (16 ) Translation adjustments (86 ) 117 (9 ) Balance, end of the year $ 1,525 $ 1,914 $ 194
Property, Plant and Equipment Estimated Useful Lives [Table Text Block]	Asset Estimated useful life Computer equipment and software 3-10 Furniture and fixtures 5-7 Equipment 5-20 Leasehold improvements Shorter of useful life or term of lease

Note 3 - Revenue by Product G_2

Note 3 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Years Ended December 31, 2018 2017 2016 Revenue Percentage Revenue Percentage Revenue Percentage Orthobiologics $ 93,556 89 % $ 93,816 87 % $ 89,695 87 % Dermal 396 0 % 2,755 3 % 2,759 3 % Surgical 5,514 5 % 5,262 5 % 5,427 5 % Other 6,065 6 % 5,950 5 % 5,051 5 % $ 105,531 100 % $ 107,783 100 % $ 102,932 100 %
Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]	Years Ended December 31, 2018 2017 2016 Total Percentage of Total Percentage of Total Percentage of Geographic Location: United States $ 85,351 81 % $ 92,905 82 % $ 83,972 81 % Europe 11,730 11 % 12,435 11 % 10,953 11 % Other 8,474 8 % 8,080 7 % 8,454 8 % Total $ 105,555 100 % $ 113,420 100 % $ 103,379 100 %
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Years Ended December 31, 2018 2017 United States $ 51,385 $ 52,828 Italy 2,726 3,355 Total $ 54,111 $ 56,183

Note 5 - Fair Value Measureme_2

Note 5 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at Reporting Date Using December 31, 2018 Quoted Prices in Significant Other Significant Amortized Cost Cash equivalents: Money Market Funds $ 4,984 $ 4,984 $ - $ - $ 4,984 Investments: U.S. treasury bills $ 69,972 $ 69,972 $ - $ - $ 69,972 Fair Value Measurements at Reporting Date Using December 31, 2017 Quoted Prices in Significant Other Significant Amortized Cost Cash equivalents: Money market funds $ 5,893 $ 5,893 $ - $ - $ 5,893 Bank certificates of deposit 500 - 500 - 500 Total cash equivalents $ 6,393 $ 5,893 $ 500 $ - $ 6,393 Investments: Bank certificates of deposit $ 24,000 $ - $ 24,000 $ - $ 24,000

Note 6 - Earnings Per Share (_2

Note 6 - Earnings Per Share ("EPS") (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Years Ended December 31, 2018 2017 2016 Shares used in the calculation of basic earnings per share 14,442 14,575 14,682 Effect of dilutive securities: Stock options, SARs, RSAs and RSUs 247 493 434 Diluted shares used in the calculation of earnings per share 14,689 15,068 15,116

Note 7 - Inventories (Tables)

Note 7 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2018 2017 Raw materials $ 13,688 $ 11,296 Work-in-process 4,626 6,062 Finished goods 6,819 4,677 Total $ 25,133 $ 22,035 Inventories $ 21,300 $ 22,035 Other long-term assets 3,833 -

Note 8 - Property and Equipme_2

Note 8 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2018 2017 Equipment and software $ 39,646 $ 37,137 Furniture and fixtures 2,014 1,947 Leasehold improvements 33,801 31,459 Construction in progress 2,720 5,830 Subtotal 78,181 76,373 Less accumulated depreciation (24,070 ) (20,190 ) Total $ 54,111 $ 56,183

Note 9 - Acquired Intangible _2

Note 9 - Acquired Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]	December 31, 2018 December 31, 2017 Gross Value Accumulated Accumulated Net Book Accumulated Accumulated Net Book Useful Developed technology $ 17,100 $ (2,824 ) $ (8,672 ) $ 5,604 $ (2,550 ) $ (7,723 ) $ 6,827 15 In-process research & development 4,406 (1,168 ) - 3,238 (1,015 ) 3,391 Indefinite Distributor relationships 4,700 (415 ) (4,285 ) - (415 ) (4,285 ) - 5 Patents 1,000 (169 ) (482 ) 349 (152 ) (431 ) 417 16 Elevess trade name 1,000 - (1,000 ) - - (1,000 ) - 9 Total $ 28,206 $ (4,576 ) $ (14,439 ) $ 9,191 $ (4,132 ) $ (13,439 ) $ 10,635

Note 10 - Goodwill (Tables)

Note 10 - Goodwill (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Goodwill [Table Text Block]	December 31, Balance, beginning $ 8,218 Effect of foreign currency adjustments (367 ) Balance, ending $ 7,851

Note 11 - Accrued Expenses (Tab

Note 11 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2018 2017 Compensation and related expenses $ 4,446 $ 2,893 Professional fees 1,989 448 Voluntary recall 116 - Research grants 400 419 Clinical trial costs 577 2,318 Income taxes payable 385 - Other 233 248 Total $ 8,146 $ 6,326

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2019 $ 1,879 2020 1,917 2021 1,924 2022 1,672 2023 414 2024 and thereafter 897 Total $ 8,703

Note 13 - Equity Incentive Pl_2

Note 13 - Equity Incentive Plan (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2018 2017 2016 Risk free interest rate 2.15% - 2.82% 1.60% - 1.86% 0.94% - 1.55% Expected volatility 37.12% - 45.61% 38.74% - 44.31% 47.33% - 51.61% Expected life (years) 4.0 - 4.5 4.0 4.5 Expected dividend yield 0.00% 0.00% 0.00%
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Twelve Months Ended December 31, 2018 2017 Grants: Stock options 199,970 440,688 RSAs 64,578 26,306 RSUs 15,457 9,970 Exercises: Stock options 284,548 12,941 SARs - 5,000
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	2018 2017 2016 Cost of product revenue $ (160 ) $ 439 $ 148 Research & development 851 564 467 Selling, general & administrative 10,355 4,804 2,777 Total stock-based compensation expense $ 11,046 $ 5,807 $ 3,392
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]	2018 Number of Weighted Options and SARs outstanding at beginning of year 1,327,200 $ 33.70 Granted 199,970 $ 58.11 Cancelled (104,629 ) $ 50.19 Expired (1,079 ) $ 46.49 Exercised (284,548 ) $ 10.14 Options and SARs outstanding at end of year 1,136,914 $ 42.06
Schedule of Share-based Compensation, Exercisable Stock Options and Stock Appreciation Rights Award Activity [Table Text Bloc]	Number Weighted Avg Weighted Average Incentive stock options 139,674 $ 24.53 4.1 Non-qualified stock options 453,790 $ 40.74 3.2 Performance awards 100,963 $ 40.72 3.1 Stock appreciation rights 35,250 $ 6.36 1.1
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	2018 Number of Weighted Unvested at Beginning of year 229,226 $ 42.47 Granted 80,035 $ 58.84 Cancelled (126,946 ) $ 42.47 Vested/Released (123,232 ) $ 50.80 Unvested at end of year 59,083 $ 47.26

Note 16 - Income Taxes (Tables)

Note 16 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Years ended December 31, 2018 2017 2016 Income before income taxes Domestic $ 26,227 $ 48,446 $ 50,181 Foreign (3,020 ) (2,244 ) 689 $ 23,207 $ 46,202 $ 50,870 Years ended December 31, 2018 2017 2016 Provision for (benefit from) income taxes: Current provision: Federal $ 4,783 $ 12,608 $ 14,982 State 1,644 2,737 3,265 Foreign 405 31 302 6,832 15,376 18,549 Deferred provision: Federal (992 ) (426 ) (70 ) State (152 ) (68 ) (84 ) Foreign (1,203 ) (496 ) (72 ) (2,347 ) (990 ) (226 ) Total provision $ 4,485 $ 14,386 $ 18,323
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2018 2017 Deferred tax assets: Net operating loss carry forward, foreign $ 1,382 $ 959 Stock-based compensation expense 3,148 2,309 Foreign currency exchange 363 265 Accrued expenses and other 818 496 Inventory reserve 1,500 740 Deferred tax assets $ 7,211 $ 4,769 December 31, 2018 2017 Deferred tax liabilities: Acquisition-related Intangibles $ (2,405 ) $ (2,743 ) Depreciation (8,348 ) (7,419 ) Deferred tax liabilities $ (10,753 ) $ (10,162 ) Net deferred tax liabilities $ (3,542 ) $ (5,393 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Years ended December 31, 2018 2017 2016 Statutory federal income tax rate 21.0 % 35.0 % 35.0 % State tax expense, net of federal benefit 5.5 % 4.8 % 4.5 % Impact of rate change on deferred taxes 0.0 % (4.9 %) 0.0 % Permanent items, including nondeductible expenses (1.4 %) 0.1 % 0.1 % State investment tax credit (0.2 %) (0.7 %) (0.1 %) Federal, state and foreign research and development credits (3.4 %) (1.4 %) (0.9 %) Foreign rate differential (0.4 %) 0.5 % (0.1 %) Domestic production deduction 0.0 % (2.8 %) (2.9 %) Stock compensation (4.8 %) (0.2 %) 0.1 % Non-deductible Section 162(m) compensation limitation 4.3 % 0.7 % 0.3 % Foreign derived intangible income deduction (1.3 %) 0.0 % 0.0 % Effective income tax rate 19.3 % 31.1 % 36.0 %

Note 18 - Quarterly Financial_2

Note 18 - Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Quarterly Financial Information [Table Text Block]	Year 2018 Quarter ended Quarter ended Quarter ended Quarter ended Product revenue $ 26,950 $ 26,781 $ 30,542 $ 21,258 Total revenue 26,956 26,787 30,548 21,264 Cost of product revenue 7,001 8,282 8,152 7,845 Gross profit on product revenue 19,949 18,499 22,390 13,413 Net income $ 7,717 $ 7,599 $ 10,092 $ (6,686 ) Per common share information: Basic net income per share $ 0.54 $ 0.53 $ 0.69 $ (0.46 ) Basic common shares outstanding 14,168 14,237 14,652 14,679 Diluted net income per share $ 0.54 $ 0.53 $ 0.68 $ (0.46 ) Diluted common shares outstanding 14,299 14,377 14,915 14,679 Year 2017 Quarter ended Quarter ended Quarter ended Quarter ended Product revenue $ 28,884 $ 27,178 $ 28,340 $ 23,381 Total revenue 29,388 27,184 33,462 23,386 Cost of product revenue 8,716 6,250 6,315 6,083 Gross profit on product revenue 20,168 20,928 22,025 17,298 Net income $ 8,067 $ 6,887 $ 11,369 $ 5,493 Per common share information: Basic net income per share $ 0.55 $ 0.47 $ 0.78 $ 0.38 Basic common shares outstanding 14,596 14,579 14,588 14,576 Diluted net income per share $ 0.53 $ 0.46 $ 0.76 $ 0.37 Diluted common shares outstanding 15,141 15,115 15,044 15,043

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2019
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total	$ (700,000)	$ 2,500,000	$ (700,000)
Foreign Currency Transaction Gain (Loss), before Tax, Total	(400,000)	700,000	(300,000)
Contract with Customer, Liability, Total	0
Inventory, Noncurrent, Total	3,833,000
Inventory, Net, Current and Noncurrent		22,000,000
Inventory Adjustments, Total	3,500,000	1,700,000
Allocated Share-based Compensation Expense, Total	$ 11,046,000	5,807,000	3,392,000
Number of Operating Segments	1
Number of Reportable Segments	1
Performance Shares [Member]
Allocated Share-based Compensation Expense, Total	$ 700,000	$ 800,000	$ 300,000
Minimum [Member]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member] | Subsequent Event [Member] | Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset				$ 20,000,000
Operating Lease, Liability, Total				30,000,000
Maximum [Member]
Property, Plant and Equipment, Useful Life	16 years
Maximum [Member] | Subsequent Event [Member] | Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset				23,000,000
Operating Lease, Liability, Total				$ 35,000,000
Other Noncurrent Assets [Member]
Inventory, Noncurrent, Total	$ 3,800,000
Accounts Receivable [Member] | Customer Concentration Risk [Member] | DePuy Mitek Inc [Member]
Concentration Risk, Percentage	75.00%	68.00%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Balance, beginning of the year	$ 1,914	$ 194	$ 167
Provision for doubtful accounts	57	1,609	52
Amounts recovered	(360)
Amounts written off		(6)	(16)
Translation adjustments	(86)	117	(9)
Balance, end of the year	$ 1,525	$ 1,914	$ 194

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2018
Minimum [Member]
Estimated useful life (Year)	5 years
Minimum [Member] | Computer Equipment and Software [Member]
Estimated useful life (Year)	3 years
Minimum [Member] | Furniture and Fixtures [Member]
Estimated useful life (Year)	5 years
Minimum [Member] | Equipment [Member]
Estimated useful life (Year)	5 years
Maximum [Member]
Estimated useful life (Year)	16 years
Maximum [Member] | Computer Equipment and Software [Member]
Estimated useful life (Year)	10 years
Maximum [Member] | Furniture and Fixtures [Member]
Estimated useful life (Year)	7 years
Maximum [Member] | Equipment [Member]
Estimated useful life (Year)	20 years

Note 3 - Revenue by Product G_3

Note 3 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information (Details Textual) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Dec. 31, 2011

Dec. 31, 2003

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Revenue from Contract with Customer, Excluding Assessed Tax, Total

$ 26,956,000

$ 26,787,000

$ 30,548,000

$ 21,264,000

$ 29,388,000

$ 27,184,000

$ 33,462,000

$ 23,386,000

$ 105,555,000

$ 113,420,000

$ 103,379,000

Inventory Recall Expense

$ 1,100,000

$ 900,000

Mitek ORTHOVISC Agreement [Member]

License Agreement Term

10 years

License Agreement Additional Term

5 years

Mitek MONOVISC Agreement [Member]

License Agreement Term

15 years

Revenue Recognition, Milestone Method, Revenue Milestone in Twelve Month Period

$ 100,000,000

Mitek MONOVISC Agreement [Member] | Milestone Revenue [Member]

Revenue from Contract with Customer, Excluding Assessed Tax, Total

$ 0

$ 5,000,000

$ 0

Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | DePuy Mitek Inc [Member]

Concentration Risk, Percentage

73.00%

73.00%

75.00%

Note 3 - Revenue by Product G_4

Note 3 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information - Product Revenue by Product Group (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 26,956	$ 26,787	$ 30,548	$ 21,264	$ 29,388	$ 27,184	$ 33,462	$ 23,386	$ 105,555	$ 113,420	$ 103,379
Orthobiologics [Member]
Revenue									$ 93,556	$ 93,816	$ 89,695
Percentage of Product Revenue									89.00%	87.00%	87.00%
Dermal [Member]
Revenue									$ 396	$ 2,755	$ 2,759
Percentage of Product Revenue									0.00%	3.00%	3.00%
Surgical [Member]
Revenue									$ 5,514	$ 5,262	$ 5,427
Percentage of Product Revenue									5.00%	5.00%	5.00%
Manufactured Product, Other [Member]
Revenue									$ 6,065	$ 5,950	$ 5,051
Percentage of Product Revenue									6.00%	5.00%	5.00%
Product [Member]
Revenue	$ 26,950	$ 26,781	$ 30,542	$ 21,258	$ 28,884	$ 27,178	$ 28,340	$ 23,381	$ 105,531	$ 107,783	$ 102,932
Percentage of Product Revenue									100.00%	100.00%	100.00%

Note 3 - Revenue by Product G_5

Note 3 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information - Total Revenue by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 26,956	$ 26,787	$ 30,548	$ 21,264	$ 29,388	$ 27,184	$ 33,462	$ 23,386	$ 105,555	$ 113,420	$ 103,379
Percentage of Revenue									100.00%	100.00%	100.00%
UNITED STATES
Revenue									$ 85,351	$ 92,905	$ 83,972
Percentage of Revenue									81.00%	82.00%	81.00%
Europe [Member]
Revenue									$ 11,730	$ 12,435	$ 10,953
Percentage of Revenue									11.00%	11.00%	11.00%
Other Location [Member]
Revenue									$ 8,474	$ 8,080	$ 8,454
Percentage of Revenue									8.00%	7.00%	8.00%

Note 3 - Revenue by Product G_6

Note 3 - Revenue by Product Group, by Significant Customer and by Geographic Region; Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property and equipment, net	$ 54,111	$ 56,183
UNITED STATES
Property and equipment, net	51,385	52,828
ITALY
Property and equipment, net	$ 2,726	$ 3,355

Note 4 - Investments (Details T

Note 4 - Investments (Details Textual) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
US Treasury Bill Securities [Member]
Available-for-sale Securities, Total	$ 70
Certificates of Deposit [Member]
Available-for-sale Securities, Total		$ 24

Note 5 - Fair Value Measureme_3

Note 5 - Fair Value Measurements - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Investments:
Investments	$ 69,972	$ 24,000
Estimate of Fair Value Measurement [Member]
Cash equivalents:
Cash equivalents		6,393
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents:
Cash equivalents		5,893
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents:
Cash equivalents		500
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents:
Cash equivalents
Reported Value Measurement [Member]
Cash equivalents:
Cash equivalents		6,393
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]
Cash equivalents:
Cash equivalents	4,984	5,893
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents:
Cash equivalents	4,984	5,893
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents:
Cash equivalents
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents:
Cash equivalents
Money Market Funds [Member] | Reported Value Measurement [Member]
Cash equivalents:
Cash equivalents	4,984	5,893
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member]
Cash equivalents:
Cash equivalents		500
Investments:
Investments		24,000
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents:
Cash equivalents
Investments:
Investments
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents:
Cash equivalents		500
Investments:
Investments		24,000
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents:
Cash equivalents
Investments:
Investments
Certificates of Deposit [Member] | Reported Value Measurement [Member]
Cash equivalents:
Cash equivalents		500
Investments:
Investments		$ 24,000
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member]
Investments:
Investments	69,972
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Investments:
Investments	69,972
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Investments:
Investments
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Investments:
Investments
US Treasury Securities [Member] | Reported Value Measurement [Member]
Investments:
Investments	$ 69,972

Note 6 - Earnings Per Share (_3

Note 6 - Earnings Per Share ("EPS") (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Jul. 19, 2018	May 24, 2018	Aug. 31, 2016	Feb. 29, 2016	Feb. 26, 2016	Jul. 19, 2018	Aug. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jul. 16, 2018	Aug. 26, 2016
Payments for Repurchase of Common Stock								$ 30,000		$ 25,000
Accelerated Stock Repurchase [Member] | Morgan Stanley & Co., LLC [Member]
Payments for Repurchase of Common Stock		$ 30,000			$ 25,000
Stock Repurchased and Retired During Period, Shares	400	400	100		400	800	500
Stock Repurchase Program, Remaining Authorized Repurchase Amount											$ 12,000	$ 7,500
Accelerated Share Repurchases, Final Price Paid Per Share						$ 37.18	$ 47.08
Accelerated Stock Repurchase [Member] | Morgan Stanley & Co., LLC [Member] | Common Stock [Member]
Stock Repurchase Program, Authorized Amount		$ 30,000			$ 25,000
Accelerated Share Repurchases, Initial Price Paid Per Share		$ 41.41		$ 46.40
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount								42	100	100
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount								700	500	400

Note 6 - Earnings Per Share (_4

Note 6 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Basic weighted average common shares outstanding (in shares)									14,442	14,575	14,682
Effect of dilutive securities:
Stock options, SARs, RSAs and RSUs (in shares)									247	493	434
Diluted shares used in the calculation of earnings per share (in shares)	14,299	14,377	14,915	14,679	15,141	15,115	15,044	15,043	14,689	15,068	15,116

Note 7 - Inventories (Details T

Note 7 - Inventories (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Inventory Write-down	$ 4,419	$ 695	$ 654
Nonsaleable Inventory [Member]
Inventory Write-down	800
HA Raw Materials [Member]
Inventory Write-down	1,300
HYAFF-based Products [Member]
Inventory Write-down	$ 1,200

Note 7 - Inventories - Summary

Note 7 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Raw materials	$ 13,688	$ 11,296
Work-in-process	4,626	6,062
Finished goods	6,819	4,677
Total	25,133	22,035
Inventories, net	21,300	22,035
Inventory, Noncurrent, Total	$ 3,833

Note 8 - Property and Equipme_3

Note 8 - Property and Equipment (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Depreciation, Total	$ 4.9	$ 3.3	$ 2.7

Note 8 - Property and Equipme_4

Note 8 - Property and Equipment - Property and Equipment at Cost (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, plant and equipment, gross	$ 78,181	$ 76,373
Less accumulated depreciation	(24,070)	(20,190)
Total	54,111	56,183
Equipment and Software [Member]
Property, plant and equipment, gross	39,646	37,137
Furniture and Fixtures [Member]
Property, plant and equipment, gross	2,014	1,947
Leasehold Improvements [Member]
Property, plant and equipment, gross	33,801	31,459
Construction in Progress [Member]
Property, plant and equipment, gross	$ 2,720	$ 5,830

Note 9 - Acquired Intangible _3

Note 9 - Acquired Intangible Assets, Net (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Amortization of Intangible Assets, Total	$ 1	$ 1	$ 1.1
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	1
Finite-Lived Intangible Assets, Amortization Expense, Year Two	1
Finite-Lived Intangible Assets, Amortization Expense, Year Five	2.1
Finite-Lived Intangible Assets, Amortization Expense, Year Three	1
Finite-Lived Intangible Assets, Amortization Expense, Year Four	$ 1

Note 9 - Acquired Intangible _4

Note 9 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Gross Value	$ 28,206
Accumulated Currency Translation Adjustment	(4,576)	$ (4,132)
Accumulated Amortization	(14,439)	(13,439)
Intangible assets, net	9,191	10,635
In Process Research and Development [Member]
Gross Value	4,406
Accumulated Currency Translation Adjustment	(1,168)	(1,015)
Accumulated Amortization
Intangible assets, net	3,238	3,391
Developed Technology Rights [Member]
Gross Value	17,100
Accumulated Currency Translation Adjustment	(2,824)	(2,550)
Accumulated Amortization	(8,672)	(7,723)
Intangible assets, net	$ 5,604	6,827
Useful life (Year)	15 years
Distribution Rights [Member]
Gross Value	$ 4,700
Accumulated Currency Translation Adjustment	(415)	(415)
Accumulated Amortization	$ (4,285)	(4,285)
Useful life (Year)	5 years
Net Book Value, abandonment
Patents [Member]
Gross Value	1,000
Accumulated Currency Translation Adjustment	(169)	(152)
Accumulated Amortization	(482)	(431)
Intangible assets, net	$ 349	417
Useful life (Year)	16 years
Elevess Trade Name [Member]
Gross Value	$ 1,000
Accumulated Currency Translation Adjustment
Accumulated Amortization	(1,000)	(1,000)
Intangible assets, net
Useful life (Year)	9 years

Note 10 - Goodwill (Details Tex

Note 10 - Goodwill (Details Textual) $ in Thousands	Nov. 30, 2018USD ($)
Goodwill, Impaired, Accumulated Impairment Loss	$ 0

Note 10 - Goodwill - Changes in

Note 10 - Goodwill - Changes in the Carrying Value of Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Balance	$ 8,218
Effect of foreign currency adjustments	(367)
Balance	$ 7,851

Note 11 - Accrued Expenses (Det

Note 11 - Accrued Expenses (Details Textual) - USD ($) $ in Millions	Mar. 08, 2018	Dec. 31, 2018
Recall Payable		$ 0.1
Former Chief Executive Officer [Member]
Severance Benefit, For A One Year Post Retirement Consulting Agreement	$ 0.3
Severance Benefit Following Retirement	$ 1.7
Severance Benefit Following Retirement, Term	1 year 180 days

Note 11 - Accrued Expenses - Su

Note 11 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Compensation and related expenses	$ 4,446	$ 2,893
Professional fees	1,989	448
Voluntary recall	116
Research grants	400	419
Clinical trial costs	577	2,318
Income taxes payable	385
Other	233	248
Total	$ 8,146	$ 6,326

Note 12 - Commitments and Con_3

Note 12 - Commitments and Contingencies (Details Textual) $ in Thousands	Oct. 09, 2015USD ($)ft²	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Operating Leases, Rent Expense, Total		$ 1,800	$ 1,800	$ 1,300
Standard and Extended Product Warranty Accrual, Ending Balance		$ 0	0
European Headquarters Facility [Member]
Area of Real Estate Property | ft²	33,000
Lessee Leasing Arrangements, Term of Contract	15 years
Lessee Leasing Arrangements, Number of Renewal Terms	3
Lessee Leasing Arrangements, Renewal Term	6 years
Lessee Leasing Arrangements Ability to Withdraw With Penalty	6 years
Lessee Leasing Arrangements Ability to Withdrawn Without Penalty	9 years
Lessee Leasing Arrangements Initial Yearly Rent	$ 300
Construction in Progress, Gross			3,100
European Headquarters Facility [Member] | Deposits and Other Assets, Noncurrent [Member]
Lessee Leasing Arrangements, Additional Tenant Improvements			$ 800

Note 12 - Commitments and Con_4

Note 12 - Commitments and Contingencies - Future Lease Commitments (Details) $ in Thousands	Dec. 31, 2018USD ($)
2,019	$ 1,879
2,020	1,917
2,021	1,924
2,022	1,672
2,023	414
2024 and thereafter	897
Total	$ 8,703

Note 13 - Equity Incentive Pl_3

Note 13 - Equity Incentive Plan (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jun. 13, 2017	Jun. 18, 2013	Jun. 07, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 20.01	$ 16.87	$ 16.65
Allocated Share-based Compensation Expense, Total		$ 11,046	$ 5,807	$ 3,392
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense		$ 1,500	400	600
Share-based Compensation Arrangement by Share-based Payment Award Options and Stock Appreciation Rights Vested and Expected to Vest Outstanding Weighted Average Exercise Price		$ 42.06
Share-based Compensation Arrangement by Share-based Payment Award Options and Stock Ppreciation Rights Vested and Expected to Vest Outstanding Aggregate Intrinsic Value		$ 5,000
Share-based Compensation Arrangement by Share-based Payment Award, Options and Stock Appreciation Rights, Exercises in Period, Total Intrinsic Value		8,500	500	2,100
Share-based Compensation Arrangement by Share-based Payment Award Options and Stock Appreciation Rights Vested in Period Fair Value		$ 6,700	2,100	1,300
Chief Executive Officer [Member]
Allocated Share-based Compensation Expense, Total	$ 6,200
Employee Stock Option [Member]
Share-based Compensation Arrangement Evaluation of Expected Volatility Assumption to Historical Volatility Average Period		4 years 182 days
Stock Options, SARs and Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		1,136,914
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 4,400
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 146 days
Restricted Stock and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 6,800	$ 2,300	$ 1,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 58.84	$ 52.03	$ 38.11
The 2017 Plan [Member]
Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs					2
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					1,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		900,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
The 2017 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		1 year
The 2017 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Amended Two Thousand Three Plan [Member]
Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs							1.9
Second Amended Two Thousand Three Plan [Member]
Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs						1.5

Note 13 - Equity Incentive Pl_4

Note 13 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Risk free interest rate
Expected volatility
Expected life (years) (Year)		4 years	4 years 182 days
Expected dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Risk free interest rate	2.15%	1.60%	0.94%
Expected volatility	37.12%	38.74%	47.33%
Expected life (years) (Year)	4 years
Expected dividend yield
Maximum [Member]
Risk free interest rate	2.82%	1.86%	1.55%
Expected volatility	45.61%	44.31%	51.61%
Expected life (years) (Year)	4 years 182 days
Expected dividend yield

Note 13 - Equity Incentive Pl_5

Note 13 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee Stock Option [Member]
Grants:
Stock options (in shares)	199,970	440,688
Exercises:
Stock options (in shares)	284,548	12,941
Restricted Stock [Member]
Grants:
Restricted stock grants (in shares)	64,578	26,306
Restricted Stock Units (RSUs) [Member]
Grants:
Restricted stock grants (in shares)	15,457	9,970
Stock Appreciation Rights (SARs) [Member]
Exercises:
SARs (in shares)		5,000

Note 13 - Equity Incentive Pl_6

Note 13 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Stock-based compensation expense	$ 11,046	$ 5,807	$ 3,392
Cost of Sales [Member]
Stock-based compensation expense	(160)	439	148
Research and Development Expense [Member]
Stock-based compensation expense	851	564	467
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 10,355	$ 4,804	$ 2,777

Note 13 - Equity Incentive Pl_7

Note 13 - Equity Incentive Plan - Stock Options and SAR's Activity (Details)	12 Months Ended
	Dec. 31, 2018$ / shares	Dec. 31, 2017$ / shares
Options and SARs outstanding	1,327,200
Options and SAR's outstanding, Weighted Average Exercise Price Per Share (in dollars per share)	$ 42.06	$ 33.70
Options and SAR's Granted	199,970
Options and SAR's Granted, Weighted Average Exercise Price Per Share (in dollars per share)	$ 58.11
Options and SAR's Cancelled	(104,629)
Options and SAR's Cancelled, Weighted Average Exercise Price Per Share (in dollars per share)	$ 50.19
Options and SAR's Expired	(1,079)
Options and SAR's Expired, Weighted Average Exercise Price Per Share (in dollars per share)	$ 46.49
Options and SAR's Exercised	(284,548)
Options and SAR's Exercised, Weighted Average Exercise Price Per Share (in dollars per share)	$ 10.14
Options and SARs outstanding	1,136,914

Note 13 - Equity Incentive Pl_8

Note 13 - Equity Incentive Plan - Summary of Exercisable Options and SAR's (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Incentive Stock Options [Member]
Exercisable Options and SAR's outstanding (in shares) | shares	139,674
Exercisable Options and SAR's, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 24.53
Exercisable Options and SAR's, Weighted Average Remaining Term (Year)	4 years 36 days
Non-qualified Stock Options [Member]
Exercisable Options and SAR's outstanding (in shares) | shares	453,790
Exercisable Options and SAR's, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 40.74
Exercisable Options and SAR's, Weighted Average Remaining Term (Year)	3 years 73 days
Performance Shares [Member]
Exercisable Options and SAR's outstanding (in shares) | shares	100,963
Exercisable Options and SAR's, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 40.72
Exercisable Options and SAR's, Weighted Average Remaining Term (Year)	3 years 36 days
Stock Appreciation Rights (SARs) [Member]
Exercisable Options and SAR's outstanding (in shares) | shares	35,250
Exercisable Options and SAR's, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 6.36
Exercisable Options and SAR's, Weighted Average Remaining Term (Year)	1 year 36 days

Note 13 - Equity Incentive Pl_9

Note 13 - Equity Incentive Plan - Restricted Stock Activity (Details) - Restricted Stock and Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Unvested at Beginning of year (in shares)	229,226
Unvested at Beginning of year, weighted average grant date fair value (in dollars per share)	$ 47.26	$ 42.47
Granted (in shares)	80,035
Granted, weighted average grant date fair value (in dollars per share)	$ 58.84
Cancelled (in shares)	(126,946)
Cancelled, weighted average grant date fair value (in dollars per share)	$ 42.47
Vested/Released (in shares)	(123,232)
Vested/Released, weighted average grant date fair value (in dollars per share)	$ 50.80
Unvested at end of year (in shares)	59,083	229,226

Note 14 - Employee Benefit Pl_2

Note 14 - Employee Benefit Plan (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	140.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	5.00%
Defined Contribution Plan, Employer Matching Contribution, Amount	$ 0.8	$ 0.6	$ 0.6

Note 16 - Income Taxes (Details

Note 16 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Dec. 22, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	21.00%	35.00%	35.00%
Operating Loss Carryforwards, Total		$ 5,800
Unrecognized Tax Benefits, Ending Balance		0	$ 0
Income Tax Expense (Benefit), Total		4,485	14,386	$ 18,323
Accounting Standards Update 2016-09 [Member]
Income Tax Expense (Benefit), Total		$ 1,500	$ (400)
Domestic Tax Authority [Member]
Open Tax Year		2015 2016 2017
Foreign Tax Authority [Member] | Ministry of Economic Affairs and Finance, Italy [Member]
Open Tax Year		2012 2013 2014 2015 2016 2017
State and Local Jurisdiction [Member]
Open Tax Year		2015 2016 2017

Note 16 - Income Taxes - Compon

Note 16 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Domestic	$ 26,227	$ 48,446	$ 50,181
Foreign	(3,020)	(2,244)	689
Income before income taxes	23,207	46,202	50,870
Current provision:
Federal	4,783	12,608	14,982
State	1,644	2,737	3,265
Foreign	405	31	302
	6,832	15,376	18,549
Deferred provision:
Federal	(992)	(426)	(70)
State	(152)	(68)	(84)
Foreign	(1,203)	(496)	(72)
	(2,347)	(990)	(226)
Total provision	$ 4,485	$ 14,386	$ 18,323

Note 16 - Income Taxes - Signif

Note 16 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Net operating loss carry forward, foreign	$ 1,382	$ 959
Stock-based compensation expense	3,148	2,309
Foreign currency exchange	363	265
Accrued expenses and other	818	496
Inventory reserve	1,500	740
Deferred tax assets	7,211	4,769
Acquisition-related Intangibles	(2,405)	(2,743)
Depreciation	(8,348)	(7,419)
Deferred tax liabilities	(10,753)	(10,162)
Net deferred tax liabilities	$ (3,542)	$ (5,393)

Note 16 - Income Taxes - Reconc

Note 16 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details)	Dec. 22, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statutory federal income tax rate	35.00%	21.00%	35.00%	35.00%
State tax expense, net of federal benefit		5.50%	4.80%	4.50%
Impact of rate change on deferred taxes		0.00%	(4.90%)	0.00%
Permanent items, including nondeductible expenses		(1.40%)	0.10%	0.10%
State investment tax credit		(0.20%)	(0.70%)	(0.10%)
Federal, state and foreign research and development credits		(3.40%)	(1.40%)	(0.90%)
Foreign rate differential		(0.40%)	0.50%	(0.10%)
Domestic production deduction		0.00%	(2.80%)	(2.90%)
Stock compensation		(4.80%)	(0.20%)	0.10%
Non-deductible Section 162(m) compensation limitation		4.30%	0.70%	0.30%
Foreign derived intangible income deduction		(1.30%)	0.00%	0.00%
Effective income tax rate		19.30%	31.10%	36.00%

Note 17 - Revolving Credit Ag_2

Note 17 - Revolving Credit Agreement (Details Textual) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	Oct. 24, 2017	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument, Term	5 years
Line of Credit Facility, Current Borrowing Capacity	$ 50,000
Line of Credit Facility, Additional Borrowing Capacity	50,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000
Line of Credit Facility, Commitment Fee Percentage	0.25%
Long-term Line of Credit, Total		$ 0	$ 0
Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	0.25%
Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Federal Funds Effective Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	0.50%
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	1.00%

Note 18 - Quarterly Financial_3

Note 18 - Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue from Contract with Customer, Excluding Assessed Tax, Total	$ 26,956	$ 26,787	$ 30,548	$ 21,264	$ 29,388	$ 27,184	$ 33,462	$ 23,386	$ 105,555	$ 113,420	$ 103,379
Cost of product revenue	7,001	8,282	8,152	7,845	8,716	6,250	6,315	6,083	31,280	27,364	24,027
Gross profit on product revenue	19,949	18,499	22,390	13,413	20,168	20,928	22,025	17,298
Net income	$ 7,717	$ 7,599	$ 10,092	$ (6,686)	$ 8,067	$ 6,887	$ 11,369	$ 5,493	$ 18,722	$ 31,816	$ 32,547
Basic net income per share (in dollars per share)	$ 0.54	$ 0.53	$ 0.69	$ (0.46)	$ 0.55	$ 0.47	$ 0.78	$ 0.38	$ 1.30	$ 2.18	$ 2.22
Basic common shares outstanding (in shares)	14,168	14,237	14,652	14,679	14,596	14,579	14,588	14,576
Diluted net income per share (in dollars per share)	$ 0.54	$ 0.53	$ 0.68	$ (0.46)	$ 0.53	$ 0.46	$ 0.76	$ 0.37	$ 1.27	$ 2.11	$ 2.15
Diluted common shares outstanding (in shares)	14,299	14,377	14,915	14,679	15,141	15,115	15,044	15,043	14,689	15,068	15,116
Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total	$ 26,950	$ 26,781	$ 30,542	$ 21,258	$ 28,884	$ 27,178	$ 28,340	$ 23,381	$ 105,531	$ 107,783	$ 102,932